Elotuzumab,Abbexa,abx831163

Elotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SLAMF7/CD319, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148. 1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U. S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.